Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs Pfizer Inc — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $36.86 (market cap $3.56B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 44.5× GraniteShares 2x Long NVDA Daily ETF's market cap, and Pfizer Inc pays a 6.18% dividend while GraniteShares 2x Long NVDA Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and Pfizer Inc for 158 Days on average.
| NVDL | PFE | |
|---|---|---|
Market Cap | $3.56B | $158.56B |
Volume | 9,740,643 | 44,138,282 |
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $29.02 |
52-Week Low | $21.76 | $23.67 |
Typical Hold Time | 15 Days | 158 Days |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL (GraniteShares 2x Long NVDA Daily ETF) trades at $36.86, down 6.85% in the last session. Technical indicators show a bullish overall signal with moving averages supporting upward momentum while oscillators remain neutral. Recent news highlights Nvidia's strong Q2 2027 earnings beat and ongoing AI theme strength, though the leveraged ETF has underperformed NVDA's direct returns over the past year.
The outlook remains tied to Nvidia's AI leadership and market performance, with technical support at $36 and resistance at $39. Key risks include leverage decay and NVDA's high valuation, while institutional interest in AI and positive analyst coverage provide potential upside catalysts for the leveraged ETF structure.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
